Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors.
暂无分享,去创建一个
M. Burgess | R. Riedel | M. Gounder | B. V. Van Tine | P. Dileo | H. Gelderblom | S. Stacchiotti | B. Vincenzi | S. Kummar | P. Schöffski | T. Alcindor | L. Davis | G. Grignani | B. Kasper | F. Mazzeo | R. Chugh | S. Attia | S. Chawla | J. Charlson | E. Palmerini | H. Bailey | H. Deshpande | E. Loggers | N. Federman | G. Tinoco | G. D'Amato | R. Ratan | P. Merriam | J. Pressey | L. Hartner | N. Bui | C. Benson | G. Cote | L. Lapeire | B. Wilky | W. V. D. van der Graaf | T. Philip | S. Moody | L. Smith | Peter Reichardt | Allison Lim | Stephanie Moody
[1] N. Federman. Molecular pathogenesis of desmoid tumor and the role of γ-secretase inhibition , 2022, npj Precision Oncology.
[2] R. Riedel,et al. Evolving strategies for management of desmoid tumor , 2022, Cancer.
[3] J. Fryzek,et al. The epidemiology of desmoid tumors in Denmark. , 2022, Cancer epidemiology.
[4] Robin L. Jones,et al. Development of a Disease-Specific Health-Related Quality of Life Questionnaire (DTF-QoL) for Patients with Desmoid-Type Fibromatosis , 2022, Cancers.
[5] D. Campanacci,et al. Extra-abdominal desmoid tumor fibromatosis: a multicenter EMSOS study , 2021, BMC cancer.
[6] H. Cho,et al. Factors Associated with Disease Stabilization of Desmoid-Type Fibromatosis , 2020, Clinics in orthopedic surgery.
[7] Robin L. Jones,et al. The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. , 2020, European journal of cancer.
[8] J. Paty,et al. Prospective development of a patient‐reported outcomes instrument for desmoid tumors or aggressive fibromatosis , 2020, Cancer.
[9] Robin L. Jones,et al. Desmoid fibromatosis through the patients’ eyes: time to change the focus and organisation of care? , 2018, Supportive Care in Cancer.
[10] A. Jimeno,et al. Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor , 2018, Annals of Surgical Oncology.
[11] U. Lendahl,et al. Notch Signaling in Development, Tissue Homeostasis, and Disease. , 2017, Physiological reviews.
[12] Jiayong Liu,et al. Efficacy of vinorelbine combined with low-dose methotrexate for treatment of inoperable desmoid tumor and prognostic factor analysis. , 2017, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.
[13] J. Blay,et al. An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG) , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] S. Carter,et al. Outcome of surgery for primary and recurrent desmoid-type fibromatosis. A retrospective case series of 174 patients , 2017, Annals of medicine and surgery.
[15] Xiaoye Hu,et al. High-intensity focused ultrasound treatment for intra-abdominal desmoid tumors: a report of four cases , 2016, Journal of Medical Ultrasonics.
[16] M. Gounder. Notch inhibition in desmoids: “Sure it works in practice, but does it work in theory?” , 2015, Cancer.
[17] C. Creighton,et al. Targeting the notch pathway: A potential therapeutic approach for desmoid tumors , 2015, Cancer.
[18] G. Sethuraman,et al. Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings , 2014, Current medical research and opinion.
[19] Sherry X. Yang,et al. Targeting notch signaling pathway in cancer: clinical development advances and challenges. , 2014, Pharmacology & therapeutics.
[20] T. Golde,et al. γ-Secretase inhibitors and modulators. , 2013, Biochimica et biophysica acta.
[21] S. Bonvalot,et al. Spontaneous Regression of Primary Abdominal Wall Desmoid Tumors: More Common than Previously Thought , 2013, Annals of Surgical Oncology.
[22] A. Oza,et al. A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503) , 2012, British Journal of Cancer.
[23] K. Blennow,et al. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. , 2012, Archives of neurology.
[24] C. Raut,et al. Optimal Approach to Sporadic Desmoid Tumors: From Radical Surgery to Observation. Time for a Consensus? , 2012, Annals of Surgical Oncology.
[25] R. Thurston,et al. Vasomotor symptoms and menopause: findings from the Study of Women's Health across the Nation. , 2011, Obstetrics and gynecology clinics of North America.
[26] J. Blay,et al. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] B. Bui,et al. A critical analysis of treatment strategies in desmoid tumours: a review of a series of 106 cases. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.